{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000344","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.063324+00:00","generated_at":"2026-06-19T01:36:20.613525+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alnylam Q4 2022 product revenue $262M (+35% YoY); guides 2023 revenue $1.2-1.285B","bullets":["Q4 2022 net product revenue $262M; full year $894M (+35% YoY). GAAP net loss $1.13B for 2022 vs $853M in 2021.","ONPATTRO Q4 rev $122M, AMVUTTRA $69M; total TTR rev $651M for 2022 (+37% YoY).","sNDA for ONPATTRO in ATTR cardiomyopathy accepted by FDA; PDUFA date Oct 8, 2023; advisory committee planned.","2023 guidance: combined net product revenue $1.2B-$1.285B; collaboration and royalty revenue also guided.","Cash $2.19B at year-end; appointed Carolyn Bertozzi to board; Amy Schulman becomes Chair."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000344","json":"https://secwatch.observer/filing/0001157523-23-000344.json","markdown":"https://secwatch.observer/filing/0001157523-23-000344.md","text":"https://secwatch.observer/filing/0001157523-23-000344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/a53337940.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:36:20.613525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"404e126bc3659491653bdf9980bf14db61ce053b","claim":"ALNYLAM PHARMACEUTICALS, INC. reported the year ending December 31, 2023 results: revenue $1,200 Million to $1,285 Million. Guidance initiated.","evidence_excerpt":"Provides 2023 Combined Net Product Revenue Guidance of $1,200 Million to $1,285 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ending December 31, 2023"},{"label":"Revenue","value":"$1,200 Million to $1,285 Million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"93e3382b46b92d6a9324f66405f5dae82a5e688d","claim":"ALNYLAM PHARMACEUTICALS, INC. reported the year ended December 31, 2022 results: revenue $894 Million.","evidence_excerpt":"Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$894 Million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"df93fb6dbb6d0d3e1cef7cf64b614fd85e3a4374","claim":"ALNYLAM PHARMACEUTICALS, INC. reported the quarter ended December 31, 2022 results: revenue $262 Million.","evidence_excerpt":"Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$262 Million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}